Literature DB >> 12210764

Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions.

A D Hollowood1, C E H Stewart, C M Perks, J M Pell, T Lai, D Alderson, J M P Holly.   

Abstract

Insulin-like growth factor binding protein-3 (IGFBP-3) is one of six high affinity-binding proteins that share a common function in regulating the bioavailability of the insulin-like growth factors. The six binding proteins have highly conserved C- and N-terminals that are essential to this function. Additionally, they all have specific functions on cellular homeostasis independent to the regulation of the insulin-like growth factors. It has previously been shown that insulin-like growth factor binding protein-3 can accentuate UV-induced apoptosis in a human carcinoma cell line. Using the KYSE 190 oesophageal carcinoma cell line we have demonstrated that a 15 amino acid (aa) peptide that lies within the mid-region of the protein can mimic the effect of the intact protein. This region contains the serine residues Ser(111) and Ser(113). Using two protocols, we modified these serine residues and have shown that both phosphorylation and derivatization of IGFBP-3 can negate the accentuation of UV-induced cell death. These three independent pieces of evidence support the hypothesis that the variable mid-region is responsible for the specific pro-apoptotic functions of IGFBP-3, and suggest that phosphorylation may provide a mechanism for regulation of this action. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210764     DOI: 10.1002/jcb.10223

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Novel actions of IGFBP-3 on intracellular signaling pathways of insulin-secreting cells.

Authors:  Xiaoyan Chen; Robert J Ferry
Journal:  Growth Horm IGF Res       Date:  2005-11-04       Impact factor: 2.372

2.  The effects of insulin-like growth factor binding protein-3 (IGFBP-3) on T47D breast cancer cells enriched for IGFBP-3 binding sites.

Authors:  Suresh Mishra; Liam J Murphy
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

3.  IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.

Authors:  Jamie McIntosh; Godwin Dennison; Jeff M P Holly; Caroline Jarrett; Alexandra Frankow; Emily J Foulstone; Zoe E Winters; Claire M Perks
Journal:  J Biol Chem       Date:  2010-09-17       Impact factor: 5.157

4.  DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

Review 5.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

6.  Enhancing the apoptotic potential of insulin-like growth factor-binding protein-3 in prostate cancer by modulation of CK2 phosphorylation.

Authors:  Laura J Cobb; Hemal Mehta; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2009-06-25

7.  Intrinsic, Pro-Apoptotic Effects of IGFBP-3 on Breast Cancer Cells are Reversible: Involvement of PKA, Rho, and Ceramide.

Authors:  Claire M Perks; Carla Burrows; Jeff M P Holly
Journal:  Front Endocrinol (Lausanne)       Date:  2011-05-16       Impact factor: 5.555

8.  Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.

Authors:  Sarah B Vestey; Claire M Perks; Chandan Sen; Caroline J Calder; Jeff M P Holly; Zoe E Winters
Journal:  Breast Cancer Res       Date:  2004-11-23       Impact factor: 6.466

9.  In silico interaction of insulin-like growth factor binding protein 3 with insulin-like growth factor 1.

Authors:  Elham Jafari; Ali Gheysarzadeh; Karim Mahnam; Rezvan Shahmohammadi; Amir Ansari; Hadi Bakhtyari; Mohammad Reza Mofid
Journal:  Res Pharm Sci       Date:  2018-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.